12:00 AM
 | 
Jul 12, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NOX-E36: Phase Ib started

Noxxon began a double-blind, placebo-controlled, German Phase Ib trial to evaluate 0.0625, 0.125 and 0.25 mg/kg intravenous NOX-E36...

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >